http://www.porot-assurances.com/article/Everyone-has-to-stick---.html
Prostate cancer is the most common cancer diagnoserdin men. Nearly 220,000 men were diagnosed with the diseaslast year, according to the . Philip Sass, the Pa., biopharmaceutical company's executive vice president and chiedfoperating officer, said the agreement adds to Morphetek's existingg collaborative relationship with NCI to develop novek therapies to treat various types of "The NCI brings significant expertise in the evaluationj and validation of lead antibodies to cancer-specifi proprietary targets," Sass "which complements Morphotek's expertise in the developmenft of antibodies as potential cancedr treatments through biological and immunological mechanisms.
" Moprhotek is a subsidiarg of , a Japanese pharmaceutical company. It is developing treatments for rheumatoid arthritis, and infectious disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment